Finasteride (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Finasteride" in English language version.

refsWebsite

Global rank English rank

86nih.gov

4^th place

65doi.org

2^nd place

43web.archive.org

1^st place

31semanticscholar.org

11^th place

8^th place

16books.google.com

3^rd place

7fda.gov

447^th place

338^th place

3worldcat.org

5^th place

3europa.eu

68^th place

117^th place

2medicines.org.uk

3,823^rd place

2,387^th place

2drugs.com

399^th place

333^rd place

2clincalc.com

3,912^th place

2,496^th place

2reuters.com

49^th place

47^th place

2nytimes.com

7^th place

1nhs.uk

1,989^th place

1,528^th place

1handle.net

102^nd place

76^th place

1jaad.org

low place

1wiley.com

222^nd place

297^th place

1cancer.gov

1,684^th place

1,350^th place

1universitypressscholarship.com

6,703^rd place

4,200^th place

1mhra.gov.uk

low place

1touro.edu

low place

1afr.com

2,149^th place

1,198^th place

1miamiherald.com

752^nd place

484^th place

1zenodo.org

621^st place

380^th place

1bbc.co.uk

8^th place

10^th place

1harvard.edu

18^th place

17^th place

1medscape.com

719^th place

636^th place

1ipoef.org

low place

1rxsolutions.com

low place

1theaustralian.com.au

965^th place

579^th place

1smh.com.au

132^nd place

96^th place

1transfusionguidelines.org

low place

afr.com (Global: 2,149^th place; English: 1,198^th place)

Margo J (26 September 2012). "Looking at care with a critical eye". Australian Financial Review. Archived from the original on 14 November 2012.

bbc.co.uk (Global: 8^th place; English: 10^th place)

"The extraordinary case of the Guevedoces". BBC News. 20 September 2015. Archived from the original on 13 August 2020. Retrieved 3 September 2018.

books.google.com (Global: 3^rd place; English: 3^rd place)

Lemke TL, Williams DA (2008). Foye's Principles of Medicinal Chemistry (6th ed.). Lippincott Williams & Wilkins. pp. 1286–. ISBN 978-0-7817-6879-5. Archived from the original on 10 January 2023. Retrieved 4 December 2017.
Blume-Peytavi U, Whiting DA, Trüeb RM (26 June 2008). Hair Growth and Disorders. Springer Science & Business Media. p. 369. ISBN 978-3-540-46911-7. Archived from the original on 10 January 2023. Retrieved 10 December 2016.
Ferri FF (2014). Ferri's Clinical Advisor 2015 E-Book: 5 Books in 1. Elsevier Health Sciences. p. 580. ISBN 978-0-323-08430-7. Archived from the original on 10 January 2023. Retrieved 7 May 2020.
Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 483. ISBN 978-3-527-60749-5. Archived from the original on 10 January 2023. Retrieved 7 May 2020.
Sataloff RT, Sclafani AP (30 November 2015). Sataloff's Comprehensive Textbook of Otolaryngology: Head & Neck Surgery: Facial Plastic and Reconstructive Surgery. JP Medical Ltd. pp. 400–. ISBN 978-93-5152-459-5. Archived from the original on 10 January 2023. Retrieved 4 December 2017.
Habif TP (23 April 2015). Clinical Dermatology. Elsevier Health Sciences. pp. 934–. ISBN 978-0-323-26607-9. Archived from the original on 10 January 2023. Retrieved 22 October 2016.
Preedy VR (2012). Handbook of Hair in Health and Disease. Springer Science & Business Media. pp. 89–. ISBN 978-90-8686-728-8. Archived from the original on 10 January 2023. Retrieved 6 May 2018.
Wu JJ (18 October 2012). Comprehensive Dermatologic Drug Therapy E-Book. Elsevier Health Sciences. pp. 361–. ISBN 978-1-4557-3801-4. Archived from the original on 10 January 2023. Retrieved 6 May 2018.
Bostwick DG, Cheng L (24 January 2014). Urologic Surgical Pathology E-Book. Elsevier Health Sciences. pp. 402–. ISBN 978-0-323-08619-6.
Cordes EH (2014). Hallelujah Moments: Tales of Drug Discovery. Oxford University Press. ISBN 978-0-19-933714-9. Archived from the original on 10 January 2023. Retrieved 21 June 2020.
Burger A, Abraham DJ (20 February 2003). Burger's Medicinal Chemistry and Drug Discovery, Autocoids, Diagnostics, and Drugs from New Biology. Wiley. p. 439. ISBN 978-0-471-37030-7. Archived from the original on 10 January 2023. Retrieved 4 December 2017.
Doherty AM (2003). Annual Reports in Medicinal Chemistry. Academic Press. pp. 353–. ISBN 978-0-12-040538-1. Archived from the original on 10 January 2023. Retrieved 4 December 2017.
Index Nominum 2000: International Drug Directory. Taylor & Francis. 2000. p. 443. ISBN 978-3-88763-075-1.
Morton IK, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 121–. ISBN 978-94-011-4439-1.
Bycroft BW, Payne DJ (9 August 2013). Dictionary of Antibiotics and Related Substances: with CD-ROM, Second Edition. CRC Press. pp. 816–. ISBN 978-1-4822-8215-3. Archived from the original on 10 January 2023. Retrieved 6 May 2018.
Danby FW (27 January 2015). Acne: Causes and Practical Management. John Wiley & Sons. pp. 147–. ISBN 978-1-118-23277-4. Archived from the original on 10 January 2023. Retrieved 24 March 2019.

cancer.gov (Global: 1,684^th place; English: 1,350^th place)

"Finasteride for Prostate Cancer Prevention". National Cancer Institute. 28 August 2013. Archived from the original on 6 February 2020. Retrieved 8 February 2020.

clincalc.com (Global: 3,912^th place; English: 2,496^th place)

"Top 300 of 2023". ClinCalc. Archived from the original on 12 August 2025. Retrieved 12 August 2025.
"Finasteride Drug Usage Statistics, United States, 2013–2022". ClinCalc. Retrieved 18 August 2025.

doi.org (Global: 2^nd place; English: 2^nd place)

Piraccini BM, Blume-Peytavi U, Scarci F, Jansat JM, Falqués M, Otero R, et al. (February 2022). "Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial". Journal of the European Academy of Dermatology and Venereology. 36 (2): 286–294. doi:10.1111/jdv.17738. PMC 9297965. PMID 34634163.
Samba Reddy D, Ramanathan G (September 2012). "Finasteride inhibits the disease-modifying activity of progesterone in the hippocampus kindling model of epileptogenesis". Epilepsy & Behavior. 25 (1): 92–97. doi:10.1016/j.yebeh.2012.05.024. PMC 3444667. PMID 22835430.
Tacklind J, Fink HA, Macdonald R, Rutks I, Wilt TJ (October 2010). "Finasteride for benign prostatic hyperplasia". The Cochrane Database of Systematic Reviews. 2010 (10): CD006015. doi:10.1002/14651858.CD006015.pub3. PMC 8908761. PMID 20927745.{{cite journal}}: CS1 maint: article number as page number (link)
Zakhem GA, Goldberg JE, Motosko CC, Cohen BE, Ho RS (July 2019). "Sexual dysfunction in men taking systemic dermatologic medication: A systematic review". Journal of the American Academy of Dermatology. 81 (1): 163–172. doi:10.1016/j.jaad.2019.03.043. PMID 30905792. S2CID 85497115.
Varothai S, Bergfeld WF (July 2014). "Androgenetic alopecia: an evidence-based treatment update". American Journal of Clinical Dermatology. 15 (3): 217–230. doi:10.1007/s40257-014-0077-5. PMID 24848508. S2CID 31245042.
Zakhem GA, Goldberg JE, Motosko CC, Cohen BE, Ho RS (July 2019). "Sexual dysfunction in men taking systemic dermatologic medication: A systematic review". Journal of the American Academy of Dermatology. 81 (1): 163–172. doi:10.1016/j.jaad.2019.03.043. PMID 30905792. S2CID 85497115. In studies addressing reversibility, most of these patients have resolution of sexual adverse effects after discontinuation of finasteride, and many have improvement of adverse effects over time with continued finasteride use. However, some studies describe a subset of patients with persistent adverse effects after discontinuation... Level 1 evidence evaluating sexual dysfunction as a primary outcome was available for finasteride.
Traish AM (January 2020). "Post-finasteride syndrome: a surmountable challenge for clinicians". Fertility and Sterility. 113 (1): 21–50. doi:10.1016/j.fertnstert.2019.11.030. PMID 32033719. S2CID 211064052.
Smith AB, Carson CC (June 2009). "Finasteride in the treatment of patients with benign prostatic hyperplasia: a review". Therapeutics and Clinical Risk Management. 5 (3): 535–545. doi:10.2147/tcrm.s6195. PMC 2710385. PMID 19707263.
Corona G, Tirabassi G, Santi D, Maseroli E, Gacci M, Dicuio M, et al. (July 2017). "Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis". Andrology. 5 (4): 671–678. doi:10.1111/andr.12353. hdl:11380/1132897. PMID 28453908. S2CID 3577324.
Kanti V, Messenger A, Dobos G, Reygagne P, Finner A, Blumeyer A, et al. (January 2018). "Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men – short version". Journal of the European Academy of Dermatology and Venereology. 32 (1): 11–22. doi:10.1111/jdv.14624. PMID 29178529.
Adil A, Godwin M (July 2017). "The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis". Journal of the American Academy of Dermatology. 77 (1): 136–141.e5. doi:10.1016/j.jaad.2017.02.054. PMID 28396101. S2CID 46036459.
Adil A, Godwin M (1 July 2017). "The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis". Journal of the American Academy of Dermatology. 77 (1): 136–141.e5. doi:10.1016/j.jaad.2017.02.054. ISSN 0190-9622. PMID 28396101.
Gupta A, Mays R, Dotzert M, Versteeg S, Shear N, Piguet V (2018). "Efficacy of non-surgical treatments for androgenetic alopecia: a systematic review and network meta-analysis". Journal of the European Academy of Dermatology and Venereology. 32 (12): 2112–2125. doi:10.1111/jdv.15081. ISSN 1468-3083. PMID 29797431.
Han SS, Park YT, Yoo JH, Park TH, Kim KJ (1 January 2004). "Comparative Evaluation of Hair Density and Grouped Hair Unit Pattern between Androgenetic Alopecia and Normal Scalp". Annals of Dermatology. 16 (1): 1–8. doi:10.5021/ad.2004.16.1.1. ISSN 1013-9087.
Yim E, Nole KL, Tosti A (December 2014). "5α-Reductase inhibitors in androgenetic alopecia". Current Opinion in Endocrinology, Diabetes, and Obesity. 21 (6): 493–498. doi:10.1097/MED.0000000000000112. PMID 25268732. S2CID 30008068.
Gupta AK, Charrette A (April 2014). "The efficacy and safety of 5α-reductase inhibitors in androgenetic alopecia: a network meta-analysis and benefit-risk assessment of finasteride and dutasteride". The Journal of Dermatological Treatment. 25 (2): 156–161. doi:10.3109/09546634.2013.813011. PMID 23768246. S2CID 24833568.
Levy LL, Emer JJ (August 2013). "Female pattern alopecia: current perspectives". International Journal of Women's Health. 5: 541–556. doi:10.2147/IJWH.S49337. PMC 3769411. PMID 24039457.
Dhurat R, Sharma A, Rudnicka L, Kroumpouzos G, Kassir M, Galadari H, et al. (May 2020). "5-Alpha reductase inhibitors in androgenetic alopecia: Shifting paradigms, current concepts, comparative efficacy, and safety". Dermatologic Therapy. 33 (3): e13379. doi:10.1111/dth.13379. PMID 32279398. S2CID 215748750.{{cite journal}}: CS1 maint: article number as page number (link)
Zhou Z, Song S, Gao Z, Wu J, Ma J, Cui Y (2019). "The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia: a systematic review and meta-analysis". Clinical Interventions in Aging. 14: 399–406. doi:10.2147/CIA.S192435. PMC 6388756. PMID 30863034.
Wilt TJ, Macdonald R, Hagerty K, Schellhammer P, Tacklind J, Somerfield MR, et al. (November 2010). "5-α-Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review". BJU International. 106 (10): 1444–1451. doi:10.1111/j.1464-410X.2010.09714.x. PMID 20977593. S2CID 22178061.
Unger JM, Hershman DL, Till C, Tangen CM, Barlow WE, Ramsey SD, et al. (March 2018). "Using Medicare Claims to Examine Long-term Prostate Cancer Risk of Finasteride in the Prostate Cancer Prevention Trial". Journal of the National Cancer Institute. 110 (11): 1208–1215. doi:10.1093/jnci/djy035. PMC 6235685. PMID 29534197.
Patisaul HB, Belcher SM (18 May 2017). "Receptor and Enzyme Mechanisms as Targets for Endocrine Disruptors". Oxford Scholarship Online. Vol. 1. Oxford University Press. p. 127. doi:10.1093/acprof:oso/9780199935734.003.0005. ISBN 978-0-19-067852-4.
Walsh PC (April 2010). "Chemoprevention of prostate cancer". The New England Journal of Medicine. 362 (13): 1237–1238. doi:10.1056/NEJMe1001045. PMID 20357287.
Wang J, Zhao S, Luo L, Li E, Li X, Zhao Z (2018). "5-alpha Reductase Inhibitors and risk of male breast cancer: a systematic review and meta-analysis". International Braz J Urol. 44 (5): 865–873. doi:10.1590/S1677-5538.IBJU.2017.0531. PMC 6237523. PMID 29697934.
Narula HS, Carlson HE (August 2014). "Gynaecomastia-pathophysiology, diagnosis and treatment". Nature Reviews. Endocrinology. 10 (11): 684–698. doi:10.1038/nrendo.2014.139. PMID 25112235. S2CID 40159424. Archived from the original on 4 December 2020. Retrieved 4 July 2019.
Deepinder F, Braunstein GD (September 2012). "Drug-induced gynecomastia: an evidence-based review". Expert Opinion on Drug Safety. 11 (5): 779–795. doi:10.1517/14740338.2012.712109. PMID 22862307. S2CID 22938364.
Chung EY, Ruospo M, Natale P, Bolignano D, Navaneethan SD, Palmer SC, et al. (October 2020). "Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease". The Cochrane Database of Systematic Reviews. 2020 (10): CD007004. doi:10.1002/14651858.CD007004.pub4. PMC 8094274. PMID 33107592.{{cite journal}}: CS1 maint: article number as page number (link)
Aiman U, Haseeen MA, Rahman SZ (December 2009). "Gynecomastia: An ADR due to drug interaction". Indian Journal of Pharmacology. 41 (6): 286–287. doi:10.4103/0253-7613.59929. PMC 2846505. PMID 20407562.
Trost L, Saitz TR, Hellstrom WJ (May 2013). "Side Effects of 5-Alpha Reductase Inhibitors: A Comprehensive Review". Sexual Medicine Reviews. 1 (1): 24–41. doi:10.1002/smrj.3. PMID 27784557.
Locci A, Pinna G (October 2017). "Neurosteroid biosynthesis downregulation and changes in GABAA receptor subunit composition: A biomarker axis in stress-induced cognitive and emotional impairment". British Journal of Pharmacology. 174 (19): 3226–3241. doi:10.1111/bph.13843. PMC 5595768. PMID 28456011.
Lee S, Lee YB, Choe SJ, Lee WS (January 2019). "Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-analysis". Acta Dermato-venereologica. 99 (1): 12–17. doi:10.2340/00015555-3035. PMID 30206635.
Gur S, Kadowitz PJ, Hellstrom WJ (January 2013). "Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation". Expert Opinion on Drug Safety. 12 (1): 81–90. doi:10.1517/14740338.2013.742885. PMID 23173718. S2CID 11624116.
Kiguradze T, Temps WH, Yarnold PR, Cashy J, Brannigan RE, Nardone B, et al. (9 March 2017). "Persistent erectile dysfunction in men exposed to the 5α-reductase inhibitors, finasteride, or dutasteride". PeerJ. 5 e3020: e3020. doi:10.7717/peerj.3020. PMC 5346286. PMID 28289563.{{cite journal}}: CS1 maint: article number as page number (link)
Maksym RB, Kajdy A, Rabijewski M (December 2019). "Post-finasteride syndrome – does it really exist?". The Aging Male. 22 (4): 250–259. doi:10.1080/13685538.2018.1548589. PMID 30651009. S2CID 58569946.
Pompili M, Magistri C, Maddalena S, Mellini C, Persechino S, Baldessarini RJ (1 May 2021). "Risk of Depression Associated With Finasteride Treatment". Journal of Clinical Psychopharmacology. 41 (3): 304–309. doi:10.1097/JCP.0000000000001379. PMID 33814544. S2CID 233028103.
Gray SL, Semla TP (August 2019). "Post-finasteride syndrome". BMJ. 366. Clinical Research Ed.: l5047. doi:10.1136/bmj.l5047. PMID 31399423. S2CID 199518161.{{cite journal}}: CS1 maint: article number as page number (link)
Frye SV (2006). "Discovery and clinical development of dutasteride, a potent dual 5alpha-reductase inhibitor". Current Topics in Medicinal Chemistry. 6 (5): 405–421. doi:10.2174/156802606776743101. PMID 16719800.
Sudduth SL, Koronkowski MJ (1993). "Finasteride: the first 5α-reductase inhibitor". Pharmacotherapy. 13 (4): 309–25, discussion 325–9. doi:10.1002/j.1875-9114.1993.tb02739.x. PMID 7689728. S2CID 71103672.
Yamana K, Labrie F, Luu-The V (August 2010). "Human type 3 5α-reductase is expressed in peripheral tissues at higher levels than types 1 and 2 and its activity is potently inhibited by finasteride and dutasteride". Hormone Molecular Biology and Clinical Investigation. 2 (3): 293–299. doi:10.1515/hmbci.2010.035. PMID 25961201. S2CID 28841145.
Aggarwal S, Thareja S, Verma A, Bhardwaj TR, Kumar M (February 2010). "An overview on 5alpha-reductase inhibitors". Steroids. 75 (2): 109–153. doi:10.1016/j.steroids.2009.10.005. PMID 19879888. S2CID 44363501.
Azzouni F, Godoy A, Li Y, Mohler J (2012). "The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseases". Advances in Urology. 2012: 530121. doi:10.1155/2012/530121. PMC 3253436. PMID 22235201.{{cite journal}}: CS1 maint: article number as page number (link)
Clapauch R, Weiss RV, Rech CM (2017). "Testosterone and Women". Testosterone. Springer. pp. 319–351. doi:10.1007/978-3-319-46086-4_17. ISBN 978-3-319-46084-0. Finasteride is not actually an antiandrogen but a 5α-reductase inhibitor.
Bartsch G, Rittmaster RS, Klocker H (April 2000). "Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia". European Urology. 37 (4): 367–380. doi:10.1159/000020181. PMID 10765065. S2CID 25793400.
Kim EH, Brockman JA, Andriole GL (January 2018). "The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia". Asian Journal of Urology. 5 (1): 28–32. doi:10.1016/j.ajur.2017.11.005. PMC 5780290. PMID 29379733.
Rittmaster RS (January 1994). "Finasteride". The New England Journal of Medicine. 330 (2): 120–125. doi:10.1056/NEJM199401133300208. PMID 7505051.
Libecco JF, Bergfeld WF (April 2004). "Finasteride in the treatment of alopecia". Expert Opinion on Pharmacotherapy. 5 (4): 933–940. doi:10.1517/14656566.5.4.933. PMID 15102575. S2CID 24296644.
Shapiro J, Kaufman KD (June 2003). "Use of finasteride in the treatment of men with androgenetic alopecia (male pattern hair loss)". The Journal of Investigative Dermatology. Symposium Proceedings. 8 (1): 20–23. doi:10.1046/j.1523-1747.2003.12167.x. PMID 12894990.
Drury JE, Di Costanzo L, Penning TM, Christianson DW (July 2009). "Inhibition of human steroid 5beta-reductase (AKR1D1) by finasteride and structure of the enzyme-inhibitor complex". The Journal of Biological Chemistry. 284 (30): 19786–19790. doi:10.1074/jbc.C109.016931. PMC 2740403. PMID 19515843.
Robaire B, Henderson NA (May 2006). "Actions of 5alpha-reductase inhibitors on the epididymis". Molecular and Cellular Endocrinology. 250 (1–2): 190–195. doi:10.1016/j.mce.2005.12.044. PMID 16476520. S2CID 53464391.
Finn DA, Beadles-Bohling AS, Beckley EH, Ford MM, Gililland KR, Gorin-Meyer RE, et al. (2006). "A new look at the 5alpha-reductase inhibitor finasteride". CNS Drug Reviews. 12 (1): 53–76. doi:10.1111/j.1527-3458.2006.00053.x. PMC 6741762. PMID 16834758.
Römer B, Gass P (December 2010). "Finasteride-induced depression: new insights into possible pathomechanisms". Journal of Cosmetic Dermatology. 9 (4): 331–332. doi:10.1111/j.1473-2165.2010.00533.x. PMID 21122055. S2CID 24328589. Archived from the original on 2 December 2020. Retrieved 26 May 2019.
Gunn BG, Brown AR, Lambert JJ, Belelli D (2011). "Neurosteroids and GABA(A) Receptor Interactions: A Focus on Stress". Frontiers in Neuroscience. 5: 131. doi:10.3389/fnins.2011.00131. PMC 3230140. PMID 22164129.
Traish AM, Hassani J, Guay AT, Zitzmann M, Hansen ML (March 2011). "Adverse side effects of 5α-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients". The Journal of Sexual Medicine. 8 (3): 872–884. doi:10.1111/j.1743-6109.2010.02157.x. PMID 21176115.
Dušková M, Hill M, Stárka L (January 2010). "The influence of low dose finasteride, a type II 5α-reductase inhibitor, on circulating neuroactive steroids". Hormone Molecular Biology and Clinical Investigation. 1 (2): 95–102. doi:10.1515/HMBCI.2010.010. PMID 25961975. S2CID 28578077.
Reddy DS (2003). "Pharmacology of endogenous neuroactive steroids". Critical Reviews in Neurobiology. 15 (3–4): 197–234. doi:10.1615/critrevneurobiol.v15.i34.20. PMID 15248811.
Tian G, Stuart JD, Moss ML, Domanico PL, Bramson HN, Patel IR, et al. (March 1994). "17 beta-(N-tert-butylcarbamoyl)-4-aza-5 alpha-androstan-1-en-3-one is an active site-directed slow time-dependent inhibitor of human steroid 5 alpha-reductase 1". Biochemistry. 33 (8): 2291–2296. doi:10.1021/bi00174a041. PMID 8117686.
Azeem A, Khan ZI, Aqil M, Ahmad FJ, Khar RK, Talegaonkar S (May 2009). "Microemulsions as a surrogate carrier for dermal drug delivery". Drug Development and Industrial Pharmacy. 35 (5): 525–547. doi:10.1080/03639040802448646. PMID 19016057. S2CID 205563538.
Hamilton J (1942). "Male hormone stimulation is prerequisite and an incitant in common baldness". American Journal of Anatomy. 71 (3): 451–480. doi:10.1002/aja.1000710306.
Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE (December 1974). "Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism". Science. 186 (4170). New York, N.Y.: 1213–1215. Bibcode:1974Sci...186.1213I. doi:10.1126/science.186.4170.1213. PMID 4432067. S2CID 36427689.
Diamanti-Kandarakis E, Tolis G, Duleba AJ (1995). "Androgens and therapeutic aspects of antiandrogens in women". Journal of the Society for Gynecologic Investigation. 2 (4): 577–592. doi:10.1177/107155769500200401. PMID 9420861. S2CID 32242838.
Marks DH, Prasad S, De Souza B, Burns LJ, Senna MM (April 2020). "Topical Antiandrogen Therapies for Androgenetic Alopecia and Acne Vulgaris". American Journal of Clinical Dermatology. 21 (2): 245–254. doi:10.1007/s40257-019-00493-z. PMID 31832993. S2CID 209331373.
Marchetti PM, Barth JH (March 2013). "Clinical biochemistry of dihydrotestosterone". Annals of Clinical Biochemistry. 50 (Pt 2): 95–107. doi:10.1258/acb.2012.012159. PMID 23431485. S2CID 8325257.
Hu AC, Chapman LW, Mesinkovska NA (January 2019). "The efficacy and use of finasteride in women: a systematic review". International Journal of Dermatology. 58 (7): 759–776. doi:10.1111/ijd.14370. PMID 30604525. S2CID 58555908.
Alikhan A, Lynch PJ, Eisen DB (April 2009). "Hidradenitis suppurativa: a comprehensive review". Journal of the American Academy of Dermatology. 60 (4): 539–61, quiz 562–3. doi:10.1016/j.jaad.2008.11.911. PMID 19293006.
Nomani H, Mohammadpour AH, Moallem SM, YazdanAbad MJ, Barreto GE, Sahebkar A (December 2019). "Anti-androgen drugs in the treatment of obsessive-compulsive disorder: a systematic review". Current Medicinal Chemistry. 27 (40): 6825–6836. doi:10.2174/0929867326666191209142209. PMID 31814547. S2CID 208956450.

drugs.com (Global: 399^th place; English: 333^rd place)

"Finasteride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 25 August 2018. Retrieved 5 March 2019.
"Finasteride". Archived from the original on 8 April 2019. Retrieved 6 December 2017.

europa.eu (Global: 68^th place; English: 117^th place)

ema.europa.eu

"Measures to minimise risk of suicidal thoughts with finasteride and dutasteride medicines | European Medicines Agency (EMA)". www.ema.europa.eu. 8 May 2025. Retrieved 10 May 2025.
"Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 30 September-3 October 2024 | European Medicines Agency (EMA)". www.ema.europa.eu. 4 October 2024. Retrieved 10 May 2025.
"Finasteride- and dutasteride-containing medicinal products - referral | European Medicines Agency (EMA)". www.ema.europa.eu. 4 October 2024. Retrieved 10 May 2025.

fda.gov (Global: 447^th place; English: 338^th place)

fda.gov

"Deferral of Blood and Plasma donors – Medications". FDA. 28 July 1993. Archived from the original on 14 December 2019. Retrieved 30 January 2020.
FDA. Posted 9 June 2011. 5-alpha reductase inhibitors (5-ARIs): Label Change – Increased Risk of Prostate Cancer Archived 18 January 2017 at the Wayback Machine
FDA (11 April 2012). "Questions and Answers: Finasteride Label Changes". US FDA. Archived from the original on 18 August 2014. Retrieved 26 October 2014.
"Deferral of Blood and Plasma donors – Medications" (PDF). FDA. 28 July 1993. Archived from the original (PDF) on 8 February 2017. Retrieved 4 February 2017.

accessdata.fda.gov

"PROPECIA Prescribing Information" (PDF). US Food & Drug Administration / Merck & Co., Inc. Archived from the original (PDF) on 10 February 2017. Retrieved 30 January 2020.
"PROSCAR Prescribing Information" (PDF). US Food & Drug Administration / Merck & Co., Inc. Archived from the original (PDF) on 10 February 2017. Retrieved 30 January 2020.
FDA. "Patent Expiration for Propecia". Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Archived from the original on 26 October 2016. Retrieved 17 August 2007.

handle.net (Global: 102^nd place; English: 76^th place)

hdl.handle.net

Corona G, Tirabassi G, Santi D, Maseroli E, Gacci M, Dicuio M, et al. (July 2017). "Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis". Andrology. 5 (4): 671–678. doi:10.1111/andr.12353. hdl:11380/1132897. PMID 28453908. S2CID 3577324.

harvard.edu (Global: 18^th place; English: 17^th place)

ui.adsabs.harvard.edu

Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE (December 1974). "Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism". Science. 186 (4170). New York, N.Y.: 1213–1215. Bibcode:1974Sci...186.1213I. doi:10.1126/science.186.4170.1213. PMID 4432067. S2CID 36427689.

ipoef.org (Global: low place; English: low place)

"Past Inventor of the Year Award Winners". ipoef.org. Intellectual Property Owners Education Foundation. 18 March 2013. Archived from the original on 25 June 2020. Retrieved 21 June 2020.

jaad.org (Global: low place; English: low place)

Adil A, Godwin M (1 July 2017). "The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis". Journal of the American Academy of Dermatology. 77 (1): 136–141.e5. doi:10.1016/j.jaad.2017.02.054. ISSN 0190-9622. PMID 28396101.

medicines.org.uk (Global: 3,823^rd place; English: 2,387^th place)

"Propecia 1 mg Film-Coated Tablets - Summary of Product Characteristics (SmPC)". (emc). 27 July 2020. Archived from the original on 20 September 2020. Retrieved 29 September 2020.
"Proscar 5mg film-coated Tablets - Summary of Product Characteristics (SmPC)". (emc). 10 July 2020. Archived from the original on 24 September 2020. Retrieved 29 September 2020.

medscape.com (Global: 719^th place; English: 636^th place)

emedicine.medscape.com

Isfort AH, Emerick JE, Paz RA (11 November 2016). "5-Alpha-Reductase Deficiency". WebMD. News & Perspective Drugs & Diseases CME & Education Academy Consult, Drugs & Diseases > Pediatrics: General Medicine. Archived from the original on 6 August 2020. Retrieved 25 October 2014.

mhra.gov.uk (Global: low place; English: low place)

Medicines and Healthcare products Regulatory Agency Drug Safety Update. December 2009 Finasteride: potential risk of male breast cancer Archived 25 October 2014 at the Wayback Machine

miamiherald.com (Global: 752^nd place; English: 484^th place)

Marchalik D (4 February 2017). "Watch for these potential side effects in drug Trump reportedly takes for hair loss". Miami Herald. Archived from the original on 7 December 2018. Retrieved 9 December 2018.

nhs.uk (Global: 1,989^th place; English: 1,528^th place)

"Benign prostate enlargement". nhs.uk. 20 October 2017. Archived from the original on 18 October 2020. Retrieved 20 October 2020.

nih.gov (Global: 4^th place; English: 4^th place)

pubmed.ncbi.nlm.nih.gov

Piraccini BM, Blume-Peytavi U, Scarci F, Jansat JM, Falqués M, Otero R, et al. (February 2022). "Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial". Journal of the European Academy of Dermatology and Venereology. 36 (2): 286–294. doi:10.1111/jdv.17738. PMC 9297965. PMID 34634163.
Samba Reddy D, Ramanathan G (September 2012). "Finasteride inhibits the disease-modifying activity of progesterone in the hippocampus kindling model of epileptogenesis". Epilepsy & Behavior. 25 (1): 92–97. doi:10.1016/j.yebeh.2012.05.024. PMC 3444667. PMID 22835430.
Tacklind J, Fink HA, Macdonald R, Rutks I, Wilt TJ (October 2010). "Finasteride for benign prostatic hyperplasia". The Cochrane Database of Systematic Reviews. 2010 (10): CD006015. doi:10.1002/14651858.CD006015.pub3. PMC 8908761. PMID 20927745.{{cite journal}}: CS1 maint: article number as page number (link)
Zakhem GA, Goldberg JE, Motosko CC, Cohen BE, Ho RS (July 2019). "Sexual dysfunction in men taking systemic dermatologic medication: A systematic review". Journal of the American Academy of Dermatology. 81 (1): 163–172. doi:10.1016/j.jaad.2019.03.043. PMID 30905792. S2CID 85497115.
Varothai S, Bergfeld WF (July 2014). "Androgenetic alopecia: an evidence-based treatment update". American Journal of Clinical Dermatology. 15 (3): 217–230. doi:10.1007/s40257-014-0077-5. PMID 24848508. S2CID 31245042.
Zakhem GA, Goldberg JE, Motosko CC, Cohen BE, Ho RS (July 2019). "Sexual dysfunction in men taking systemic dermatologic medication: A systematic review". Journal of the American Academy of Dermatology. 81 (1): 163–172. doi:10.1016/j.jaad.2019.03.043. PMID 30905792. S2CID 85497115. In studies addressing reversibility, most of these patients have resolution of sexual adverse effects after discontinuation of finasteride, and many have improvement of adverse effects over time with continued finasteride use. However, some studies describe a subset of patients with persistent adverse effects after discontinuation... Level 1 evidence evaluating sexual dysfunction as a primary outcome was available for finasteride.
Traish AM (January 2020). "Post-finasteride syndrome: a surmountable challenge for clinicians". Fertility and Sterility. 113 (1): 21–50. doi:10.1016/j.fertnstert.2019.11.030. PMID 32033719. S2CID 211064052.
Smith AB, Carson CC (June 2009). "Finasteride in the treatment of patients with benign prostatic hyperplasia: a review". Therapeutics and Clinical Risk Management. 5 (3): 535–545. doi:10.2147/tcrm.s6195. PMC 2710385. PMID 19707263.
Corona G, Tirabassi G, Santi D, Maseroli E, Gacci M, Dicuio M, et al. (July 2017). "Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis". Andrology. 5 (4): 671–678. doi:10.1111/andr.12353. hdl:11380/1132897. PMID 28453908. S2CID 3577324.
Kanti V, Messenger A, Dobos G, Reygagne P, Finner A, Blumeyer A, et al. (January 2018). "Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men – short version". Journal of the European Academy of Dermatology and Venereology. 32 (1): 11–22. doi:10.1111/jdv.14624. PMID 29178529.
Adil A, Godwin M (July 2017). "The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis". Journal of the American Academy of Dermatology. 77 (1): 136–141.e5. doi:10.1016/j.jaad.2017.02.054. PMID 28396101. S2CID 46036459.
Adil A, Godwin M (1 July 2017). "The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis". Journal of the American Academy of Dermatology. 77 (1): 136–141.e5. doi:10.1016/j.jaad.2017.02.054. ISSN 0190-9622. PMID 28396101.
Gupta A, Mays R, Dotzert M, Versteeg S, Shear N, Piguet V (2018). "Efficacy of non-surgical treatments for androgenetic alopecia: a systematic review and network meta-analysis". Journal of the European Academy of Dermatology and Venereology. 32 (12): 2112–2125. doi:10.1111/jdv.15081. ISSN 1468-3083. PMID 29797431.
Yim E, Nole KL, Tosti A (December 2014). "5α-Reductase inhibitors in androgenetic alopecia". Current Opinion in Endocrinology, Diabetes, and Obesity. 21 (6): 493–498. doi:10.1097/MED.0000000000000112. PMID 25268732. S2CID 30008068.
Gupta AK, Charrette A (April 2014). "The efficacy and safety of 5α-reductase inhibitors in androgenetic alopecia: a network meta-analysis and benefit-risk assessment of finasteride and dutasteride". The Journal of Dermatological Treatment. 25 (2): 156–161. doi:10.3109/09546634.2013.813011. PMID 23768246. S2CID 24833568.
Levy LL, Emer JJ (August 2013). "Female pattern alopecia: current perspectives". International Journal of Women's Health. 5: 541–556. doi:10.2147/IJWH.S49337. PMC 3769411. PMID 24039457.
Dhurat R, Sharma A, Rudnicka L, Kroumpouzos G, Kassir M, Galadari H, et al. (May 2020). "5-Alpha reductase inhibitors in androgenetic alopecia: Shifting paradigms, current concepts, comparative efficacy, and safety". Dermatologic Therapy. 33 (3): e13379. doi:10.1111/dth.13379. PMID 32279398. S2CID 215748750.{{cite journal}}: CS1 maint: article number as page number (link)
Zhou Z, Song S, Gao Z, Wu J, Ma J, Cui Y (2019). "The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia: a systematic review and meta-analysis". Clinical Interventions in Aging. 14: 399–406. doi:10.2147/CIA.S192435. PMC 6388756. PMID 30863034.
Wilt TJ, Macdonald R, Hagerty K, Schellhammer P, Tacklind J, Somerfield MR, et al. (November 2010). "5-α-Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review". BJU International. 106 (10): 1444–1451. doi:10.1111/j.1464-410X.2010.09714.x. PMID 20977593. S2CID 22178061.
Unger JM, Hershman DL, Till C, Tangen CM, Barlow WE, Ramsey SD, et al. (March 2018). "Using Medicare Claims to Examine Long-term Prostate Cancer Risk of Finasteride in the Prostate Cancer Prevention Trial". Journal of the National Cancer Institute. 110 (11): 1208–1215. doi:10.1093/jnci/djy035. PMC 6235685. PMID 29534197.
Hirshburg JM, Kelsey PA, Therrien CA, Gavino AC, Reichenberg JS (July 2016). "Adverse Effects and Safety of 5-alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic Review". The Journal of Clinical and Aesthetic Dermatology. 9 (7): 56–62. PMC 5023004. PMID 27672412.
Walsh PC (April 2010). "Chemoprevention of prostate cancer". The New England Journal of Medicine. 362 (13): 1237–1238. doi:10.1056/NEJMe1001045. PMID 20357287.
Wang J, Zhao S, Luo L, Li E, Li X, Zhao Z (2018). "5-alpha Reductase Inhibitors and risk of male breast cancer: a systematic review and meta-analysis". International Braz J Urol. 44 (5): 865–873. doi:10.1590/S1677-5538.IBJU.2017.0531. PMC 6237523. PMID 29697934.
Narula HS, Carlson HE (August 2014). "Gynaecomastia-pathophysiology, diagnosis and treatment". Nature Reviews. Endocrinology. 10 (11): 684–698. doi:10.1038/nrendo.2014.139. PMID 25112235. S2CID 40159424. Archived from the original on 4 December 2020. Retrieved 4 July 2019.
Deepinder F, Braunstein GD (September 2012). "Drug-induced gynecomastia: an evidence-based review". Expert Opinion on Drug Safety. 11 (5): 779–795. doi:10.1517/14740338.2012.712109. PMID 22862307. S2CID 22938364.
Chung EY, Ruospo M, Natale P, Bolignano D, Navaneethan SD, Palmer SC, et al. (October 2020). "Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease". The Cochrane Database of Systematic Reviews. 2020 (10): CD007004. doi:10.1002/14651858.CD007004.pub4. PMC 8094274. PMID 33107592.{{cite journal}}: CS1 maint: article number as page number (link)
Aiman U, Haseeen MA, Rahman SZ (December 2009). "Gynecomastia: An ADR due to drug interaction". Indian Journal of Pharmacology. 41 (6): 286–287. doi:10.4103/0253-7613.59929. PMC 2846505. PMID 20407562.
Trost L, Saitz TR, Hellstrom WJ (May 2013). "Side Effects of 5-Alpha Reductase Inhibitors: A Comprehensive Review". Sexual Medicine Reviews. 1 (1): 24–41. doi:10.1002/smrj.3. PMID 27784557.
Locci A, Pinna G (October 2017). "Neurosteroid biosynthesis downregulation and changes in GABAA receptor subunit composition: A biomarker axis in stress-induced cognitive and emotional impairment". British Journal of Pharmacology. 174 (19): 3226–3241. doi:10.1111/bph.13843. PMC 5595768. PMID 28456011.
Lee S, Lee YB, Choe SJ, Lee WS (January 2019). "Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-analysis". Acta Dermato-venereologica. 99 (1): 12–17. doi:10.2340/00015555-3035. PMID 30206635.
Gur S, Kadowitz PJ, Hellstrom WJ (January 2013). "Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation". Expert Opinion on Drug Safety. 12 (1): 81–90. doi:10.1517/14740338.2013.742885. PMID 23173718. S2CID 11624116.
Kiguradze T, Temps WH, Yarnold PR, Cashy J, Brannigan RE, Nardone B, et al. (9 March 2017). "Persistent erectile dysfunction in men exposed to the 5α-reductase inhibitors, finasteride, or dutasteride". PeerJ. 5 e3020: e3020. doi:10.7717/peerj.3020. PMC 5346286. PMID 28289563.{{cite journal}}: CS1 maint: article number as page number (link)
Maksym RB, Kajdy A, Rabijewski M (December 2019). "Post-finasteride syndrome – does it really exist?". The Aging Male. 22 (4): 250–259. doi:10.1080/13685538.2018.1548589. PMID 30651009. S2CID 58569946.
Pompili M, Magistri C, Maddalena S, Mellini C, Persechino S, Baldessarini RJ (1 May 2021). "Risk of Depression Associated With Finasteride Treatment". Journal of Clinical Psychopharmacology. 41 (3): 304–309. doi:10.1097/JCP.0000000000001379. PMID 33814544. S2CID 233028103.
Gray SL, Semla TP (August 2019). "Post-finasteride syndrome". BMJ. 366. Clinical Research Ed.: l5047. doi:10.1136/bmj.l5047. PMID 31399423. S2CID 199518161.{{cite journal}}: CS1 maint: article number as page number (link)
Frye SV (2006). "Discovery and clinical development of dutasteride, a potent dual 5alpha-reductase inhibitor". Current Topics in Medicinal Chemistry. 6 (5): 405–421. doi:10.2174/156802606776743101. PMID 16719800.
Sudduth SL, Koronkowski MJ (1993). "Finasteride: the first 5α-reductase inhibitor". Pharmacotherapy. 13 (4): 309–25, discussion 325–9. doi:10.1002/j.1875-9114.1993.tb02739.x. PMID 7689728. S2CID 71103672.
Yamana K, Labrie F, Luu-The V (August 2010). "Human type 3 5α-reductase is expressed in peripheral tissues at higher levels than types 1 and 2 and its activity is potently inhibited by finasteride and dutasteride". Hormone Molecular Biology and Clinical Investigation. 2 (3): 293–299. doi:10.1515/hmbci.2010.035. PMID 25961201. S2CID 28841145.
Aggarwal S, Thareja S, Verma A, Bhardwaj TR, Kumar M (February 2010). "An overview on 5alpha-reductase inhibitors". Steroids. 75 (2): 109–153. doi:10.1016/j.steroids.2009.10.005. PMID 19879888. S2CID 44363501.
Azzouni F, Godoy A, Li Y, Mohler J (2012). "The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseases". Advances in Urology. 2012: 530121. doi:10.1155/2012/530121. PMC 3253436. PMID 22235201.{{cite journal}}: CS1 maint: article number as page number (link)
Bartsch G, Rittmaster RS, Klocker H (April 2000). "Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia". European Urology. 37 (4): 367–380. doi:10.1159/000020181. PMID 10765065. S2CID 25793400.
Kim EH, Brockman JA, Andriole GL (January 2018). "The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia". Asian Journal of Urology. 5 (1): 28–32. doi:10.1016/j.ajur.2017.11.005. PMC 5780290. PMID 29379733.
Rittmaster RS (January 1994). "Finasteride". The New England Journal of Medicine. 330 (2): 120–125. doi:10.1056/NEJM199401133300208. PMID 7505051.
Libecco JF, Bergfeld WF (April 2004). "Finasteride in the treatment of alopecia". Expert Opinion on Pharmacotherapy. 5 (4): 933–940. doi:10.1517/14656566.5.4.933. PMID 15102575. S2CID 24296644.
Shapiro J, Kaufman KD (June 2003). "Use of finasteride in the treatment of men with androgenetic alopecia (male pattern hair loss)". The Journal of Investigative Dermatology. Symposium Proceedings. 8 (1): 20–23. doi:10.1046/j.1523-1747.2003.12167.x. PMID 12894990.
Drury JE, Di Costanzo L, Penning TM, Christianson DW (July 2009). "Inhibition of human steroid 5beta-reductase (AKR1D1) by finasteride and structure of the enzyme-inhibitor complex". The Journal of Biological Chemistry. 284 (30): 19786–19790. doi:10.1074/jbc.C109.016931. PMC 2740403. PMID 19515843.
Robaire B, Henderson NA (May 2006). "Actions of 5alpha-reductase inhibitors on the epididymis". Molecular and Cellular Endocrinology. 250 (1–2): 190–195. doi:10.1016/j.mce.2005.12.044. PMID 16476520. S2CID 53464391.
Finn DA, Beadles-Bohling AS, Beckley EH, Ford MM, Gililland KR, Gorin-Meyer RE, et al. (2006). "A new look at the 5alpha-reductase inhibitor finasteride". CNS Drug Reviews. 12 (1): 53–76. doi:10.1111/j.1527-3458.2006.00053.x. PMC 6741762. PMID 16834758.
Römer B, Gass P (December 2010). "Finasteride-induced depression: new insights into possible pathomechanisms". Journal of Cosmetic Dermatology. 9 (4): 331–332. doi:10.1111/j.1473-2165.2010.00533.x. PMID 21122055. S2CID 24328589. Archived from the original on 2 December 2020. Retrieved 26 May 2019.
Gunn BG, Brown AR, Lambert JJ, Belelli D (2011). "Neurosteroids and GABA(A) Receptor Interactions: A Focus on Stress". Frontiers in Neuroscience. 5: 131. doi:10.3389/fnins.2011.00131. PMC 3230140. PMID 22164129.
Traish AM, Hassani J, Guay AT, Zitzmann M, Hansen ML (March 2011). "Adverse side effects of 5α-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients". The Journal of Sexual Medicine. 8 (3): 872–884. doi:10.1111/j.1743-6109.2010.02157.x. PMID 21176115.
Dusková M, Hill M, Hanus M, Matousková M, Stárka L (2009). "Finasteride treatment and neuroactive steroid formation". Prague Medical Report. 110 (3): 222–230. PMID 19655698.
Dušková M, Hill M, Stárka L (January 2010). "The influence of low dose finasteride, a type II 5α-reductase inhibitor, on circulating neuroactive steroids". Hormone Molecular Biology and Clinical Investigation. 1 (2): 95–102. doi:10.1515/HMBCI.2010.010. PMID 25961975. S2CID 28578077.
Reddy DS (2003). "Pharmacology of endogenous neuroactive steroids". Critical Reviews in Neurobiology. 15 (3–4): 197–234. doi:10.1615/critrevneurobiol.v15.i34.20. PMID 15248811.
Tian G, Stuart JD, Moss ML, Domanico PL, Bramson HN, Patel IR, et al. (March 1994). "17 beta-(N-tert-butylcarbamoyl)-4-aza-5 alpha-androstan-1-en-3-one is an active site-directed slow time-dependent inhibitor of human steroid 5 alpha-reductase 1". Biochemistry. 33 (8): 2291–2296. doi:10.1021/bi00174a041. PMID 8117686.
Azeem A, Khan ZI, Aqil M, Ahmad FJ, Khar RK, Talegaonkar S (May 2009). "Microemulsions as a surrogate carrier for dermal drug delivery". Drug Development and Industrial Pharmacy. 35 (5): 525–547. doi:10.1080/03639040802448646. PMID 19016057. S2CID 205563538.
Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE (December 1974). "Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism". Science. 186 (4170). New York, N.Y.: 1213–1215. Bibcode:1974Sci...186.1213I. doi:10.1126/science.186.4170.1213. PMID 4432067. S2CID 36427689.
Diamanti-Kandarakis E, Tolis G, Duleba AJ (1995). "Androgens and therapeutic aspects of antiandrogens in women". Journal of the Society for Gynecologic Investigation. 2 (4): 577–592. doi:10.1177/107155769500200401. PMID 9420861. S2CID 32242838.
Lee SW, Juhasz M, Mobasher P, Ekelem C, Mesinkovska NA (April 2018). "A Systematic Review of Topical Finasteride in the Treatment of Androgenetic Alopecia in Men and Women". Journal of Drugs in Dermatology. 17 (4): 457–463. PMC 6609098. PMID 29601622.
Marks DH, Prasad S, De Souza B, Burns LJ, Senna MM (April 2020). "Topical Antiandrogen Therapies for Androgenetic Alopecia and Acne Vulgaris". American Journal of Clinical Dermatology. 21 (2): 245–254. doi:10.1007/s40257-019-00493-z. PMID 31832993. S2CID 209331373.
Marchetti PM, Barth JH (March 2013). "Clinical biochemistry of dihydrotestosterone". Annals of Clinical Biochemistry. 50 (Pt 2): 95–107. doi:10.1258/acb.2012.012159. PMID 23431485. S2CID 8325257.
Hu AC, Chapman LW, Mesinkovska NA (January 2019). "The efficacy and use of finasteride in women: a systematic review". International Journal of Dermatology. 58 (7): 759–776. doi:10.1111/ijd.14370. PMID 30604525. S2CID 58555908.
Alikhan A, Lynch PJ, Eisen DB (April 2009). "Hidradenitis suppurativa: a comprehensive review". Journal of the American Academy of Dermatology. 60 (4): 539–61, quiz 562–3. doi:10.1016/j.jaad.2008.11.911. PMID 19293006.
Riis PT, Ring HC, Themstrup L, Jemec GB (December 2016). "The Role of Androgens and Estrogens in Hidradenitis Suppurativa – A Systematic Review". Acta Dermatovenerologica Croatica. 24 (4): 239–249. PMID 28128074.
Nomani H, Mohammadpour AH, Moallem SM, YazdanAbad MJ, Barreto GE, Sahebkar A (December 2019). "Anti-androgen drugs in the treatment of obsessive-compulsive disorder: a systematic review". Current Medicinal Chemistry. 27 (40): 6825–6836. doi:10.2174/0929867326666191209142209. PMID 31814547. S2CID 208956450.

ncbi.nlm.nih.gov

Piraccini BM, Blume-Peytavi U, Scarci F, Jansat JM, Falqués M, Otero R, et al. (February 2022). "Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial". Journal of the European Academy of Dermatology and Venereology. 36 (2): 286–294. doi:10.1111/jdv.17738. PMC 9297965. PMID 34634163.
Samba Reddy D, Ramanathan G (September 2012). "Finasteride inhibits the disease-modifying activity of progesterone in the hippocampus kindling model of epileptogenesis". Epilepsy & Behavior. 25 (1): 92–97. doi:10.1016/j.yebeh.2012.05.024. PMC 3444667. PMID 22835430.
Tacklind J, Fink HA, Macdonald R, Rutks I, Wilt TJ (October 2010). "Finasteride for benign prostatic hyperplasia". The Cochrane Database of Systematic Reviews. 2010 (10): CD006015. doi:10.1002/14651858.CD006015.pub3. PMC 8908761. PMID 20927745.{{cite journal}}: CS1 maint: article number as page number (link)
Smith AB, Carson CC (June 2009). "Finasteride in the treatment of patients with benign prostatic hyperplasia: a review". Therapeutics and Clinical Risk Management. 5 (3): 535–545. doi:10.2147/tcrm.s6195. PMC 2710385. PMID 19707263.
Levy LL, Emer JJ (August 2013). "Female pattern alopecia: current perspectives". International Journal of Women's Health. 5: 541–556. doi:10.2147/IJWH.S49337. PMC 3769411. PMID 24039457.
Zhou Z, Song S, Gao Z, Wu J, Ma J, Cui Y (2019). "The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia: a systematic review and meta-analysis". Clinical Interventions in Aging. 14: 399–406. doi:10.2147/CIA.S192435. PMC 6388756. PMID 30863034.
Unger JM, Hershman DL, Till C, Tangen CM, Barlow WE, Ramsey SD, et al. (March 2018). "Using Medicare Claims to Examine Long-term Prostate Cancer Risk of Finasteride in the Prostate Cancer Prevention Trial". Journal of the National Cancer Institute. 110 (11): 1208–1215. doi:10.1093/jnci/djy035. PMC 6235685. PMID 29534197.
Hirshburg JM, Kelsey PA, Therrien CA, Gavino AC, Reichenberg JS (July 2016). "Adverse Effects and Safety of 5-alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic Review". The Journal of Clinical and Aesthetic Dermatology. 9 (7): 56–62. PMC 5023004. PMID 27672412.
Wang J, Zhao S, Luo L, Li E, Li X, Zhao Z (2018). "5-alpha Reductase Inhibitors and risk of male breast cancer: a systematic review and meta-analysis". International Braz J Urol. 44 (5): 865–873. doi:10.1590/S1677-5538.IBJU.2017.0531. PMC 6237523. PMID 29697934.
Chung EY, Ruospo M, Natale P, Bolignano D, Navaneethan SD, Palmer SC, et al. (October 2020). "Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease". The Cochrane Database of Systematic Reviews. 2020 (10): CD007004. doi:10.1002/14651858.CD007004.pub4. PMC 8094274. PMID 33107592.{{cite journal}}: CS1 maint: article number as page number (link)
Aiman U, Haseeen MA, Rahman SZ (December 2009). "Gynecomastia: An ADR due to drug interaction". Indian Journal of Pharmacology. 41 (6): 286–287. doi:10.4103/0253-7613.59929. PMC 2846505. PMID 20407562.
Locci A, Pinna G (October 2017). "Neurosteroid biosynthesis downregulation and changes in GABAA receptor subunit composition: A biomarker axis in stress-induced cognitive and emotional impairment". British Journal of Pharmacology. 174 (19): 3226–3241. doi:10.1111/bph.13843. PMC 5595768. PMID 28456011.
Kiguradze T, Temps WH, Yarnold PR, Cashy J, Brannigan RE, Nardone B, et al. (9 March 2017). "Persistent erectile dysfunction in men exposed to the 5α-reductase inhibitors, finasteride, or dutasteride". PeerJ. 5 e3020: e3020. doi:10.7717/peerj.3020. PMC 5346286. PMID 28289563.{{cite journal}}: CS1 maint: article number as page number (link)
Azzouni F, Godoy A, Li Y, Mohler J (2012). "The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseases". Advances in Urology. 2012: 530121. doi:10.1155/2012/530121. PMC 3253436. PMID 22235201.{{cite journal}}: CS1 maint: article number as page number (link)
Kim EH, Brockman JA, Andriole GL (January 2018). "The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia". Asian Journal of Urology. 5 (1): 28–32. doi:10.1016/j.ajur.2017.11.005. PMC 5780290. PMID 29379733.
Drury JE, Di Costanzo L, Penning TM, Christianson DW (July 2009). "Inhibition of human steroid 5beta-reductase (AKR1D1) by finasteride and structure of the enzyme-inhibitor complex". The Journal of Biological Chemistry. 284 (30): 19786–19790. doi:10.1074/jbc.C109.016931. PMC 2740403. PMID 19515843.
Finn DA, Beadles-Bohling AS, Beckley EH, Ford MM, Gililland KR, Gorin-Meyer RE, et al. (2006). "A new look at the 5alpha-reductase inhibitor finasteride". CNS Drug Reviews. 12 (1): 53–76. doi:10.1111/j.1527-3458.2006.00053.x. PMC 6741762. PMID 16834758.
Gunn BG, Brown AR, Lambert JJ, Belelli D (2011). "Neurosteroids and GABA(A) Receptor Interactions: A Focus on Stress". Frontiers in Neuroscience. 5: 131. doi:10.3389/fnins.2011.00131. PMC 3230140. PMID 22164129.
Lee SW, Juhasz M, Mobasher P, Ekelem C, Mesinkovska NA (April 2018). "A Systematic Review of Topical Finasteride in the Treatment of Androgenetic Alopecia in Men and Women". Journal of Drugs in Dermatology. 17 (4): 457–463. PMC 6609098. PMID 29601622.

dailymed.nlm.nih.gov

"Proscar- finasteride tablet, film coated". DailyMed. 15 November 2019. Archived from the original on 26 April 2021. Retrieved 16 September 2020.
"Propecia – finasteride tablet, film coated". DailyMed. 15 November 2019. Archived from the original on 6 June 2021. Retrieved 16 September 2020.

nytimes.com (Global: 7^th place; English: 7^th place)

nytimes.com

Freudenheim M (16 February 1992). "Keeping the Pipeline Filled at Merck". The New York Times. Archived from the original on 14 March 2017. Retrieved 16 February 2017.

query.nytimes.com

Sandomir R (19 January 2006). "Skin Deep; Fighting Baldness, and Now an Olympic Ban". The New York Times. Archived from the original on 4 December 2017. Retrieved 2 May 2010.

reuters.com (Global: 49^th place; English: 47^th place)

"EU drugs regulator confirms suicidal thoughts as side effect of hair loss drug". Reuters. 8 May 2025.
"U.S. court let Merck hide secrets about popular drug's risks". Reuters. Archived from the original on 12 February 2020. Retrieved 25 March 2021. these legal briefs filed by plaintiffs' lawyers allege that in revisions to the drug's original 1997 label, Merck understated the number of men who experienced sexual symptoms in clinical trials, and how long those symptoms lasted.

rxsolutions.com (Global: low place; English: low place)

"Primary Patent Expirations for Selected High Revenue Drugs". RxNews. Prescription Solutions. Archived from the original on 21 March 2008.

semanticscholar.org (Global: 11^th place; English: 8^th place)

api.semanticscholar.org

Zakhem GA, Goldberg JE, Motosko CC, Cohen BE, Ho RS (July 2019). "Sexual dysfunction in men taking systemic dermatologic medication: A systematic review". Journal of the American Academy of Dermatology. 81 (1): 163–172. doi:10.1016/j.jaad.2019.03.043. PMID 30905792. S2CID 85497115.
Varothai S, Bergfeld WF (July 2014). "Androgenetic alopecia: an evidence-based treatment update". American Journal of Clinical Dermatology. 15 (3): 217–230. doi:10.1007/s40257-014-0077-5. PMID 24848508. S2CID 31245042.
Zakhem GA, Goldberg JE, Motosko CC, Cohen BE, Ho RS (July 2019). "Sexual dysfunction in men taking systemic dermatologic medication: A systematic review". Journal of the American Academy of Dermatology. 81 (1): 163–172. doi:10.1016/j.jaad.2019.03.043. PMID 30905792. S2CID 85497115. In studies addressing reversibility, most of these patients have resolution of sexual adverse effects after discontinuation of finasteride, and many have improvement of adverse effects over time with continued finasteride use. However, some studies describe a subset of patients with persistent adverse effects after discontinuation... Level 1 evidence evaluating sexual dysfunction as a primary outcome was available for finasteride.
Traish AM (January 2020). "Post-finasteride syndrome: a surmountable challenge for clinicians". Fertility and Sterility. 113 (1): 21–50. doi:10.1016/j.fertnstert.2019.11.030. PMID 32033719. S2CID 211064052.
Corona G, Tirabassi G, Santi D, Maseroli E, Gacci M, Dicuio M, et al. (July 2017). "Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis". Andrology. 5 (4): 671–678. doi:10.1111/andr.12353. hdl:11380/1132897. PMID 28453908. S2CID 3577324.
Adil A, Godwin M (July 2017). "The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis". Journal of the American Academy of Dermatology. 77 (1): 136–141.e5. doi:10.1016/j.jaad.2017.02.054. PMID 28396101. S2CID 46036459.
Yim E, Nole KL, Tosti A (December 2014). "5α-Reductase inhibitors in androgenetic alopecia". Current Opinion in Endocrinology, Diabetes, and Obesity. 21 (6): 493–498. doi:10.1097/MED.0000000000000112. PMID 25268732. S2CID 30008068.
Gupta AK, Charrette A (April 2014). "The efficacy and safety of 5α-reductase inhibitors in androgenetic alopecia: a network meta-analysis and benefit-risk assessment of finasteride and dutasteride". The Journal of Dermatological Treatment. 25 (2): 156–161. doi:10.3109/09546634.2013.813011. PMID 23768246. S2CID 24833568.
Dhurat R, Sharma A, Rudnicka L, Kroumpouzos G, Kassir M, Galadari H, et al. (May 2020). "5-Alpha reductase inhibitors in androgenetic alopecia: Shifting paradigms, current concepts, comparative efficacy, and safety". Dermatologic Therapy. 33 (3): e13379. doi:10.1111/dth.13379. PMID 32279398. S2CID 215748750.{{cite journal}}: CS1 maint: article number as page number (link)
Wilt TJ, Macdonald R, Hagerty K, Schellhammer P, Tacklind J, Somerfield MR, et al. (November 2010). "5-α-Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review". BJU International. 106 (10): 1444–1451. doi:10.1111/j.1464-410X.2010.09714.x. PMID 20977593. S2CID 22178061.
Narula HS, Carlson HE (August 2014). "Gynaecomastia-pathophysiology, diagnosis and treatment". Nature Reviews. Endocrinology. 10 (11): 684–698. doi:10.1038/nrendo.2014.139. PMID 25112235. S2CID 40159424. Archived from the original on 4 December 2020. Retrieved 4 July 2019.
Deepinder F, Braunstein GD (September 2012). "Drug-induced gynecomastia: an evidence-based review". Expert Opinion on Drug Safety. 11 (5): 779–795. doi:10.1517/14740338.2012.712109. PMID 22862307. S2CID 22938364.
Gur S, Kadowitz PJ, Hellstrom WJ (January 2013). "Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation". Expert Opinion on Drug Safety. 12 (1): 81–90. doi:10.1517/14740338.2013.742885. PMID 23173718. S2CID 11624116.
Maksym RB, Kajdy A, Rabijewski M (December 2019). "Post-finasteride syndrome – does it really exist?". The Aging Male. 22 (4): 250–259. doi:10.1080/13685538.2018.1548589. PMID 30651009. S2CID 58569946.
Pompili M, Magistri C, Maddalena S, Mellini C, Persechino S, Baldessarini RJ (1 May 2021). "Risk of Depression Associated With Finasteride Treatment". Journal of Clinical Psychopharmacology. 41 (3): 304–309. doi:10.1097/JCP.0000000000001379. PMID 33814544. S2CID 233028103.
Gray SL, Semla TP (August 2019). "Post-finasteride syndrome". BMJ. 366. Clinical Research Ed.: l5047. doi:10.1136/bmj.l5047. PMID 31399423. S2CID 199518161.{{cite journal}}: CS1 maint: article number as page number (link)
Sudduth SL, Koronkowski MJ (1993). "Finasteride: the first 5α-reductase inhibitor". Pharmacotherapy. 13 (4): 309–25, discussion 325–9. doi:10.1002/j.1875-9114.1993.tb02739.x. PMID 7689728. S2CID 71103672.
Yamana K, Labrie F, Luu-The V (August 2010). "Human type 3 5α-reductase is expressed in peripheral tissues at higher levels than types 1 and 2 and its activity is potently inhibited by finasteride and dutasteride". Hormone Molecular Biology and Clinical Investigation. 2 (3): 293–299. doi:10.1515/hmbci.2010.035. PMID 25961201. S2CID 28841145.
Aggarwal S, Thareja S, Verma A, Bhardwaj TR, Kumar M (February 2010). "An overview on 5alpha-reductase inhibitors". Steroids. 75 (2): 109–153. doi:10.1016/j.steroids.2009.10.005. PMID 19879888. S2CID 44363501.
Bartsch G, Rittmaster RS, Klocker H (April 2000). "Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia". European Urology. 37 (4): 367–380. doi:10.1159/000020181. PMID 10765065. S2CID 25793400.
Libecco JF, Bergfeld WF (April 2004). "Finasteride in the treatment of alopecia". Expert Opinion on Pharmacotherapy. 5 (4): 933–940. doi:10.1517/14656566.5.4.933. PMID 15102575. S2CID 24296644.
Robaire B, Henderson NA (May 2006). "Actions of 5alpha-reductase inhibitors on the epididymis". Molecular and Cellular Endocrinology. 250 (1–2): 190–195. doi:10.1016/j.mce.2005.12.044. PMID 16476520. S2CID 53464391.
Römer B, Gass P (December 2010). "Finasteride-induced depression: new insights into possible pathomechanisms". Journal of Cosmetic Dermatology. 9 (4): 331–332. doi:10.1111/j.1473-2165.2010.00533.x. PMID 21122055. S2CID 24328589. Archived from the original on 2 December 2020. Retrieved 26 May 2019.
Dušková M, Hill M, Stárka L (January 2010). "The influence of low dose finasteride, a type II 5α-reductase inhibitor, on circulating neuroactive steroids". Hormone Molecular Biology and Clinical Investigation. 1 (2): 95–102. doi:10.1515/HMBCI.2010.010. PMID 25961975. S2CID 28578077.
Azeem A, Khan ZI, Aqil M, Ahmad FJ, Khar RK, Talegaonkar S (May 2009). "Microemulsions as a surrogate carrier for dermal drug delivery". Drug Development and Industrial Pharmacy. 35 (5): 525–547. doi:10.1080/03639040802448646. PMID 19016057. S2CID 205563538.
Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE (December 1974). "Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism". Science. 186 (4170). New York, N.Y.: 1213–1215. Bibcode:1974Sci...186.1213I. doi:10.1126/science.186.4170.1213. PMID 4432067. S2CID 36427689.
Diamanti-Kandarakis E, Tolis G, Duleba AJ (1995). "Androgens and therapeutic aspects of antiandrogens in women". Journal of the Society for Gynecologic Investigation. 2 (4): 577–592. doi:10.1177/107155769500200401. PMID 9420861. S2CID 32242838.
Marks DH, Prasad S, De Souza B, Burns LJ, Senna MM (April 2020). "Topical Antiandrogen Therapies for Androgenetic Alopecia and Acne Vulgaris". American Journal of Clinical Dermatology. 21 (2): 245–254. doi:10.1007/s40257-019-00493-z. PMID 31832993. S2CID 209331373.
Marchetti PM, Barth JH (March 2013). "Clinical biochemistry of dihydrotestosterone". Annals of Clinical Biochemistry. 50 (Pt 2): 95–107. doi:10.1258/acb.2012.012159. PMID 23431485. S2CID 8325257.
Hu AC, Chapman LW, Mesinkovska NA (January 2019). "The efficacy and use of finasteride in women: a systematic review". International Journal of Dermatology. 58 (7): 759–776. doi:10.1111/ijd.14370. PMID 30604525. S2CID 58555908.
Nomani H, Mohammadpour AH, Moallem SM, YazdanAbad MJ, Barreto GE, Sahebkar A (December 2019). "Anti-androgen drugs in the treatment of obsessive-compulsive disorder: a systematic review". Current Medicinal Chemistry. 27 (40): 6825–6836. doi:10.2174/0929867326666191209142209. PMID 31814547. S2CID 208956450.

smh.com.au (Global: 132^nd place; English: 96^th place)

Staff (9 October 2008). "WADA takes Romario's drug off banned list". Sydney Morning Herald. Archived from the original on 25 September 2015. Retrieved 25 October 2014.

theaustralian.com.au (Global: 965^th place; English: 579^th place)

Staff (28 October 2008). "WADA removes Finasteride from ban list". The Australian.

touro.edu (Global: low place; English: low place)

touroscholar.touro.edu

Narula HS, Carlson HE (August 2014). "Gynaecomastia-pathophysiology, diagnosis and treatment". Nature Reviews. Endocrinology. 10 (11): 684–698. doi:10.1038/nrendo.2014.139. PMID 25112235. S2CID 40159424. Archived from the original on 4 December 2020. Retrieved 4 July 2019.

transfusionguidelines.org (Global: low place; English: low place)

"Anti-Androgens – Joint United Kingdom Blood Transfusion and Tissue Transplantation Services Professional Advisory Committee". www.transfusionguidelines.org. 1 June 2007. Archived from the original on 12 November 2020. Retrieved 13 May 2020.

universitypressscholarship.com (Global: 6,703^rd place; English: 4,200^th place)

oxford.universitypressscholarship.com

Patisaul HB, Belcher SM (18 May 2017). "Receptor and Enzyme Mechanisms as Targets for Endocrine Disruptors". Oxford Scholarship Online. Vol. 1. Oxford University Press. p. 127. doi:10.1093/acprof:oso/9780199935734.003.0005. ISBN 978-0-19-067852-4.

web.archive.org (Global: 1^st place; English: 1^st place)

"Propecia 1 mg Film-Coated Tablets - Summary of Product Characteristics (SmPC)". (emc). 27 July 2020. Archived from the original on 20 September 2020. Retrieved 29 September 2020.
"Proscar 5mg film-coated Tablets - Summary of Product Characteristics (SmPC)". (emc). 10 July 2020. Archived from the original on 24 September 2020. Retrieved 29 September 2020.
"Proscar- finasteride tablet, film coated". DailyMed. 15 November 2019. Archived from the original on 26 April 2021. Retrieved 16 September 2020.
"Propecia – finasteride tablet, film coated". DailyMed. 15 November 2019. Archived from the original on 6 June 2021. Retrieved 16 September 2020.
Lemke TL, Williams DA (2008). Foye's Principles of Medicinal Chemistry (6th ed.). Lippincott Williams & Wilkins. pp. 1286–. ISBN 978-0-7817-6879-5. Archived from the original on 10 January 2023. Retrieved 4 December 2017.
"Finasteride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 25 August 2018. Retrieved 5 March 2019.
Blume-Peytavi U, Whiting DA, Trüeb RM (26 June 2008). Hair Growth and Disorders. Springer Science & Business Media. p. 369. ISBN 978-3-540-46911-7. Archived from the original on 10 January 2023. Retrieved 10 December 2016.
Ferri FF (2014). Ferri's Clinical Advisor 2015 E-Book: 5 Books in 1. Elsevier Health Sciences. p. 580. ISBN 978-0-323-08430-7. Archived from the original on 10 January 2023. Retrieved 7 May 2020.
Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 483. ISBN 978-3-527-60749-5. Archived from the original on 10 January 2023. Retrieved 7 May 2020.
Sataloff RT, Sclafani AP (30 November 2015). Sataloff's Comprehensive Textbook of Otolaryngology: Head & Neck Surgery: Facial Plastic and Reconstructive Surgery. JP Medical Ltd. pp. 400–. ISBN 978-93-5152-459-5. Archived from the original on 10 January 2023. Retrieved 4 December 2017.
"Top 300 of 2023". ClinCalc. Archived from the original on 12 August 2025. Retrieved 12 August 2025.
"Benign prostate enlargement". nhs.uk. 20 October 2017. Archived from the original on 18 October 2020. Retrieved 20 October 2020.
Habif TP (23 April 2015). Clinical Dermatology. Elsevier Health Sciences. pp. 934–. ISBN 978-0-323-26607-9. Archived from the original on 10 January 2023. Retrieved 22 October 2016.
"Finasteride for Prostate Cancer Prevention". National Cancer Institute. 28 August 2013. Archived from the original on 6 February 2020. Retrieved 8 February 2020.
"PROPECIA Prescribing Information" (PDF). US Food & Drug Administration / Merck & Co., Inc. Archived from the original (PDF) on 10 February 2017. Retrieved 30 January 2020.
"PROSCAR Prescribing Information" (PDF). US Food & Drug Administration / Merck & Co., Inc. Archived from the original (PDF) on 10 February 2017. Retrieved 30 January 2020.
"Deferral of Blood and Plasma donors – Medications". FDA. 28 July 1993. Archived from the original on 14 December 2019. Retrieved 30 January 2020.
FDA. Posted 9 June 2011. 5-alpha reductase inhibitors (5-ARIs): Label Change – Increased Risk of Prostate Cancer Archived 18 January 2017 at the Wayback Machine
Medicines and Healthcare products Regulatory Agency Drug Safety Update. December 2009 Finasteride: potential risk of male breast cancer Archived 25 October 2014 at the Wayback Machine
Narula HS, Carlson HE (August 2014). "Gynaecomastia-pathophysiology, diagnosis and treatment". Nature Reviews. Endocrinology. 10 (11): 684–698. doi:10.1038/nrendo.2014.139. PMID 25112235. S2CID 40159424. Archived from the original on 4 December 2020. Retrieved 4 July 2019.
FDA (11 April 2012). "Questions and Answers: Finasteride Label Changes". US FDA. Archived from the original on 18 August 2014. Retrieved 26 October 2014.
Margo J (26 September 2012). "Looking at care with a critical eye". Australian Financial Review. Archived from the original on 14 November 2012.
Marchalik D (4 February 2017). "Watch for these potential side effects in drug Trump reportedly takes for hair loss". Miami Herald. Archived from the original on 7 December 2018. Retrieved 9 December 2018.
"U.S. court let Merck hide secrets about popular drug's risks". Reuters. Archived from the original on 12 February 2020. Retrieved 25 March 2021. these legal briefs filed by plaintiffs' lawyers allege that in revisions to the drug's original 1997 label, Merck understated the number of men who experienced sexual symptoms in clinical trials, and how long those symptoms lasted.
Preedy VR (2012). Handbook of Hair in Health and Disease. Springer Science & Business Media. pp. 89–. ISBN 978-90-8686-728-8. Archived from the original on 10 January 2023. Retrieved 6 May 2018.
Wu JJ (18 October 2012). Comprehensive Dermatologic Drug Therapy E-Book. Elsevier Health Sciences. pp. 361–. ISBN 978-1-4557-3801-4. Archived from the original on 10 January 2023. Retrieved 6 May 2018.
Römer B, Gass P (December 2010). "Finasteride-induced depression: new insights into possible pathomechanisms". Journal of Cosmetic Dermatology. 9 (4): 331–332. doi:10.1111/j.1473-2165.2010.00533.x. PMID 21122055. S2CID 24328589. Archived from the original on 2 December 2020. Retrieved 26 May 2019.
"The extraordinary case of the Guevedoces". BBC News. 20 September 2015. Archived from the original on 13 August 2020. Retrieved 3 September 2018.
Isfort AH, Emerick JE, Paz RA (11 November 2016). "5-Alpha-Reductase Deficiency". WebMD. News & Perspective Drugs & Diseases CME & Education Academy Consult, Drugs & Diseases > Pediatrics: General Medicine. Archived from the original on 6 August 2020. Retrieved 25 October 2014.
Freudenheim M (16 February 1992). "Keeping the Pipeline Filled at Merck". The New York Times. Archived from the original on 14 March 2017. Retrieved 16 February 2017.
Cordes EH (2014). Hallelujah Moments: Tales of Drug Discovery. Oxford University Press. ISBN 978-0-19-933714-9. Archived from the original on 10 January 2023. Retrieved 21 June 2020.
"Past Inventor of the Year Award Winners". ipoef.org. Intellectual Property Owners Education Foundation. 18 March 2013. Archived from the original on 25 June 2020. Retrieved 21 June 2020.
Burger A, Abraham DJ (20 February 2003). Burger's Medicinal Chemistry and Drug Discovery, Autocoids, Diagnostics, and Drugs from New Biology. Wiley. p. 439. ISBN 978-0-471-37030-7. Archived from the original on 10 January 2023. Retrieved 4 December 2017.
Doherty AM (2003). Annual Reports in Medicinal Chemistry. Academic Press. pp. 353–. ISBN 978-0-12-040538-1. Archived from the original on 10 January 2023. Retrieved 4 December 2017.
Bycroft BW, Payne DJ (9 August 2013). Dictionary of Antibiotics and Related Substances: with CD-ROM, Second Edition. CRC Press. pp. 816–. ISBN 978-1-4822-8215-3. Archived from the original on 10 January 2023. Retrieved 6 May 2018.
"Finasteride". Archived from the original on 8 April 2019. Retrieved 6 December 2017.
"Primary Patent Expirations for Selected High Revenue Drugs". RxNews. Prescription Solutions. Archived from the original on 21 March 2008.
FDA. "Patent Expiration for Propecia". Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Archived from the original on 26 October 2016. Retrieved 17 August 2007.
Sandomir R (19 January 2006). "Skin Deep; Fighting Baldness, and Now an Olympic Ban". The New York Times. Archived from the original on 4 December 2017. Retrieved 2 May 2010.
Staff (9 October 2008). "WADA takes Romario's drug off banned list". Sydney Morning Herald. Archived from the original on 25 September 2015. Retrieved 25 October 2014.
"Deferral of Blood and Plasma donors – Medications" (PDF). FDA. 28 July 1993. Archived from the original (PDF) on 8 February 2017. Retrieved 4 February 2017.
"Anti-Androgens – Joint United Kingdom Blood Transfusion and Tissue Transplantation Services Professional Advisory Committee". www.transfusionguidelines.org. 1 June 2007. Archived from the original on 12 November 2020. Retrieved 13 May 2020.
Danby FW (27 January 2015). Acne: Causes and Practical Management. John Wiley & Sons. pp. 147–. ISBN 978-1-118-23277-4. Archived from the original on 10 January 2023. Retrieved 24 March 2019.

wiley.com (Global: 222^nd place; English: 297^th place)

onlinelibrary.wiley.com

Gupta A, Mays R, Dotzert M, Versteeg S, Shear N, Piguet V (2018). "Efficacy of non-surgical treatments for androgenetic alopecia: a systematic review and network meta-analysis". Journal of the European Academy of Dermatology and Venereology. 32 (12): 2112–2125. doi:10.1111/jdv.15081. ISSN 1468-3083. PMID 29797431.

worldcat.org (Global: 5^th place; English: 5^th place)

search.worldcat.org

Adil A, Godwin M (1 July 2017). "The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis". Journal of the American Academy of Dermatology. 77 (1): 136–141.e5. doi:10.1016/j.jaad.2017.02.054. ISSN 0190-9622. PMID 28396101.
Gupta A, Mays R, Dotzert M, Versteeg S, Shear N, Piguet V (2018). "Efficacy of non-surgical treatments for androgenetic alopecia: a systematic review and network meta-analysis". Journal of the European Academy of Dermatology and Venereology. 32 (12): 2112–2125. doi:10.1111/jdv.15081. ISSN 1468-3083. PMID 29797431.
Han SS, Park YT, Yoo JH, Park TH, Kim KJ (1 January 2004). "Comparative Evaluation of Hair Density and Grouped Hair Unit Pattern between Androgenetic Alopecia and Normal Scalp". Annals of Dermatology. 16 (1): 1–8. doi:10.5021/ad.2004.16.1.1. ISSN 1013-9087.

zenodo.org (Global: 621^st place; English: 380^th place)

Römer B, Gass P (December 2010). "Finasteride-induced depression: new insights into possible pathomechanisms". Journal of Cosmetic Dermatology. 9 (4): 331–332. doi:10.1111/j.1473-2165.2010.00533.x. PMID 21122055. S2CID 24328589. Archived from the original on 2 December 2020. Retrieved 26 May 2019.

Finasteride (English Wikipedia)

afr.com (Global: 2,149th place; English: 1,198th place)

bbc.co.uk (Global: 8th place; English: 10th place)

books.google.com (Global: 3rd place; English: 3rd place)

cancer.gov (Global: 1,684th place; English: 1,350th place)

clincalc.com (Global: 3,912th place; English: 2,496th place)

doi.org (Global: 2nd place; English: 2nd place)

drugs.com (Global: 399th place; English: 333rd place)

europa.eu (Global: 68th place; English: 117th place)

ema.europa.eu

fda.gov (Global: 447th place; English: 338th place)

fda.gov

accessdata.fda.gov

handle.net (Global: 102nd place; English: 76th place)

hdl.handle.net

harvard.edu (Global: 18th place; English: 17th place)

ui.adsabs.harvard.edu

ipoef.org (Global: low place; English: low place)

jaad.org (Global: low place; English: low place)

medicines.org.uk (Global: 3,823rd place; English: 2,387th place)

medscape.com (Global: 719th place; English: 636th place)

emedicine.medscape.com

mhra.gov.uk (Global: low place; English: low place)

miamiherald.com (Global: 752nd place; English: 484th place)

nhs.uk (Global: 1,989th place; English: 1,528th place)

nih.gov (Global: 4th place; English: 4th place)

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

dailymed.nlm.nih.gov

nytimes.com (Global: 7th place; English: 7th place)

nytimes.com

query.nytimes.com

reuters.com (Global: 49th place; English: 47th place)

rxsolutions.com (Global: low place; English: low place)

semanticscholar.org (Global: 11th place; English: 8th place)

api.semanticscholar.org

smh.com.au (Global: 132nd place; English: 96th place)

theaustralian.com.au (Global: 965th place; English: 579th place)

touro.edu (Global: low place; English: low place)

touroscholar.touro.edu

transfusionguidelines.org (Global: low place; English: low place)

universitypressscholarship.com (Global: 6,703rd place; English: 4,200th place)

oxford.universitypressscholarship.com

web.archive.org (Global: 1st place; English: 1st place)

wiley.com (Global: 222nd place; English: 297th place)

onlinelibrary.wiley.com

worldcat.org (Global: 5th place; English: 5th place)

search.worldcat.org

zenodo.org (Global: 621st place; English: 380th place)

afr.com (Global: 2,149^th place; English: 1,198^th place)

bbc.co.uk (Global: 8^th place; English: 10^th place)

books.google.com (Global: 3^rd place; English: 3^rd place)

cancer.gov (Global: 1,684^th place; English: 1,350^th place)

clincalc.com (Global: 3,912^th place; English: 2,496^th place)

doi.org (Global: 2^nd place; English: 2^nd place)

drugs.com (Global: 399^th place; English: 333^rd place)

europa.eu (Global: 68^th place; English: 117^th place)

fda.gov (Global: 447^th place; English: 338^th place)

handle.net (Global: 102^nd place; English: 76^th place)

harvard.edu (Global: 18^th place; English: 17^th place)

medicines.org.uk (Global: 3,823^rd place; English: 2,387^th place)

medscape.com (Global: 719^th place; English: 636^th place)

miamiherald.com (Global: 752^nd place; English: 484^th place)

nhs.uk (Global: 1,989^th place; English: 1,528^th place)

nih.gov (Global: 4^th place; English: 4^th place)

nytimes.com (Global: 7^th place; English: 7^th place)

reuters.com (Global: 49^th place; English: 47^th place)

semanticscholar.org (Global: 11^th place; English: 8^th place)

smh.com.au (Global: 132^nd place; English: 96^th place)

theaustralian.com.au (Global: 965^th place; English: 579^th place)

universitypressscholarship.com (Global: 6,703^rd place; English: 4,200^th place)

web.archive.org (Global: 1^st place; English: 1^st place)

wiley.com (Global: 222^nd place; English: 297^th place)

worldcat.org (Global: 5^th place; English: 5^th place)

zenodo.org (Global: 621^st place; English: 380^th place)